Abiomed Valuation
Is ABMD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ABMD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ABMD * (MX$7565) is trading above our estimate of fair value (MX$1374.88)
Significantly Below Fair Value: ABMD * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ABMD *?
Other financial metrics that can be useful for relative valuation.
What is ABMD *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$17.19b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 15.1x |
Enterprise Value/EBITDA | 59.3x |
PEG Ratio | -26x |
Price to Earnings Ratio vs Peers
How does ABMD *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 46.3x | ||
SOON Sonova Holding | 25.3x | 10.7% | CHF15.2b |
7733 Olympus | 64.6x | 1.5% | JP¥2.6t |
COH Cochlear | 59.8x | 12.2% | AU$21.0b |
STE STERIS | 35.4x | 13.2% | US$20.4b |
ABMD * Abiomed | 64.4x | -2.5% | Mex$17.2b |
Price-To-Earnings vs Peers: ABMD * is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the peer average (26.2x).
Price to Earnings Ratio vs Industry
How does ABMD *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: ABMD * is expensive based on its Price-To-Earnings Ratio (64.4x) compared to the Global Medical Equipment industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is ABMD *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 64.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ABMD *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Apr ’25 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Mar ’25 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Feb ’25 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Jan ’25 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Dec ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Nov ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Oct ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Sep ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Aug ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Jul ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Jun ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
May ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Apr ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Mar ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Feb ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Jan ’24 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Dec ’23 | n/a | Mex$7,125.03 0% | 9.9% | Mex$7,636.77 | Mex$5,904.72 | n/a | 4 |
Nov ’23 | n/a | Mex$6,261.07 0% | 17.6% | Mex$7,493.56 | Mex$4,634.18 | n/a | 4 |
Oct ’23 | n/a | Mex$6,738.75 0% | 23.2% | Mex$8,464.94 | Mex$4,680.61 | n/a | 3 |
Sep ’23 | Mex$5,082.00 | Mex$7,077.55 +39.3% | 20.4% | Mex$8,563.58 | Mex$4,735.16 | n/a | 4 |
Aug ’23 | Mex$5,915.00 | Mex$6,882.38 +16.4% | 22.1% | Mex$8,783.82 | Mex$4,856.93 | n/a | 5 |
Jul ’23 | Mex$5,044.17 | Mex$6,987.45 +38.5% | 19.9% | Mex$8,436.55 | Mex$5,161.18 | n/a | 5 |
Jun ’23 | Mex$5,040.00 | Mex$6,965.74 +38.2% | 18.6% | Mex$8,519.25 | Mex$5,211.78 | n/a | 6 |
May ’23 | Mex$5,937.00 | Mex$7,228.08 +21.7% | 16.1% | Mex$8,673.70 | Mex$5,612.39 | n/a | 6 |
Apr ’23 | Mex$6,657.00 | Mex$7,250.94 +8.9% | 15.5% | Mex$8,442.88 | Mex$5,463.04 | n/a | 5 |
Analyst Forecast: Target price is lower than the current share price.